AI-Powered Partnership Promises Leap in Cancer Therapy with $8 Million Deal
ImmunoPrecise Antibodies collaborates with a biotech company to revolutionize cancer treatment through Antibody-Drug Conjugates (ADCs) and bispecific antibodies. The partnership, valued between $8-10 million, lasts 18-24 months and utilizes IPA’s B-cell Select™ platform and AI-driven discovery capabilities. IPA’s LENSai™ technology enhances therapeutic
